10-Hydroxycamptothecin loaded nanoparticles: Preparation and antitumor activity in mice

Journal of Controlled Release

Volumn 119, Issue 2, 2007, Pages 153-162

  Zhang, Leyang ^a   Yang, Mi ^b   Wang, Qin ^a   Li, Yuan ^a   Guo, Rui ^a   Jiang, Xiqun ^a   Yang, Changzheng ^a   Liu, Baorui ^b  

^a NANJING UNIVERSITY   (China)

^b THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

Antitumor; Biodistribution; Camptothecin; Drug delivery; Nanoparticles

Indexed keywords

ANTITUMOR; BIODISTRIBUTION; CAMPTOTHECIN;

BLOCK COPOLYMERS; CYTOTOXICITY; DRUG DELIVERY; ENCAPSULATION; ONCOLOGY; RATS;

NANOPARTICLES;

10 HYDROXYCAMPTOTHECIN; COPOLYMER; NANOPARTICLE; POLY(CAPROLACTONE CO LACTIDE); POLYCAPROLACTONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DISTRIBUTION; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MOUSE; MOUSE STRAIN; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; HUMANS; MICE; MICE, INBRED ICR; NANOPARTICLES; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248512119     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.02.013     Document Type: Article

References (34)

1. Jaxel C., W.Kohn K., Wani M.C., Wall M.E., and Prommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res. 49 (1989) 1465-1469
2. Carbonero R., and Supko J. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 8 (2002) 641-661
3. O'Leary J., and Muggia F.M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer 34 (1998) 1500-1508
4. Ohe Y., Sasaki Y., Shinkai T., Eguchi K., Tamura T., Kojima A., Kunikane H., Okamoto H., Karato A., and Ohmatsu H. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84 (1992) 972-974
5. Gupta E., Lestingi T., and Mick R. Metabolic fate of Irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54 (1994) 3723-3725
6. Hatefi A., and Amsden B. Camptothecin delivery methods. Pharm. Res. 19 (2002) 1389-1399
7. Shenderova A., Burke T., and Schwendeman S. Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm. Res. 14 (1997) 1406-1414
8. Ertl B., Platzer P., Wirth M., and Gabor F. Poly(d,l-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. J. Control. Release 61 (1999) 305-317
9. Zhang J., Xuan T., Parmar M., Ma L., Ugwu S., Ali S., and Ahmad I. Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 270 (2004) 93-107
10. Cortesi R., Esposito E., Maietti A., Menegatti E., and Nastruzzi C. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int. J. Pharm. 159 (1997) 95-103
11. Shi B., Fang C., You M., Zhang Y., Fu S., and Pei Y. Stealth MePEG-PCL micelles: effects of polymer composition on micelle physicochemical characteristics, in vitro drug release, in vivo pharmacokinetics in rats and biodistribution in S180 tumor bearing mice. Colloid Polym. Sci. 283 (2005) 954-967
12. Zhang Y., Wang C., Yang W., Shi B., and Fu S. Tri-component diblock copolymers of poly(ethylene glycol)-poly(e-caprolactone-co-lactide): synthesis, characterization and loading camptothecin. Colloid Polym. Sci. 283 (2005) 1246-1252
13. Miura H., Onishi H., Sasatsu M., and Machida Y. Antitumor characteristics of methoxypolyethylene glycol-poly(dl-lactic acid) nanoparticles containing camptothecin. J. Control. Release 97 (2004) 101-113
14. Zhang L., Hu Y., Jiang X., Yang C., Lu W., and Yang Y. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J. Control. Release 96 (2004) 135-148
15. Mu L., Elbayoumi T., and Torchilin V.P. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int. J. Pharm. 306 (2005) 142-149
16. Gref R., Minamitake Y., Peracchia M.T., Trebetskoy V.S., Torchilin V.P., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 (1994) 1600-1603
17. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-318
18. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
19. Savić R., Luo L., Eisenberg A., and Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300 (2003) 615-618
20. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54 (2002) 631-651
21. Opanasopit P., Yokoyama M., Watanabe M., Kawano K., Maitani Y., and Okano T. Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm. Res. 21 (2004) 2001-2008
22. Xie D., Hu Y., Shen Q., and Yang C. Study of polyfunctional carboxyl telechelic microspheres. J. Appl. Polym. Sci. 72 (1999) 667-676
23. Lee J., Cho E., and Cho K. Incorporation and release behavior of hydrophobic drug in functionalized poly(d,l-lactide)-block-poly(ethylene oxide) micelles. J. Control. Release 94 (2004) 323-335
24. Allen C., Maysinger D., and Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf., B Biointerfaces 16 (1999) 3-27
25. Guinebretière S., Briancon S., Fessi H., Teodorescu V., and Blanchin M. Nanocapsules of biodegradable polymers: preparation and characterization by direct high resolution electron microscopy. Mater. Sci. Eng., C, Biomim. Mater., Sens. Syst. 21 (2002) 137-142
26. Hawley A.E., Illum L., and Davis S.S. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm. Res. 14 (1997) 657-661
27. Hatefi A., Knight D., and Amsden B. A biodegradable injectable thermoplastic for localized camptothecin delivery. J. Pharm. Sci. 93 (2004) 1195-1204
28. Kawano K., Watanabe M., Yamamoto T., Yokoyama M., Opanasopit P., Okano T., and Maitani Y. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J. Control. Release 112 (2006) 329-332
29. Peracchia M.T., Fattal E., Desmaele D., Besnard M., Noel J.P., Gomis J.M., Appel M., d'Angelo J., and Couvreur P. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 60 (1999) 121-128
30. Koshkina N., Waldrep J., and Knight V. Camptothecins and lung cancer: improved delivery systems by aerosol. Curr. Cancer Drug Targets 3 (2003) 251-264
31. Yang S., Lu L., Cai Y., Zhu J., Liang B., and Yang C. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 59 (1999) 299-307
32. Calvo P., Gouritin B., Chacun H., Desmaele D., D'Angelo J., Noel J.P., Georgin D., Fattal E., Andreux J., and Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18 (2001) 1157-1166
33. Chiannilkulchai N., Ammoury N., Caillou B., Devissaguet J., and Couvreur P. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol. 26 (1990) 122-126
34. Soma C.E., Dubernet C., Barratt G., Benita S., and Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. J. Control. Release 68 (2000) 283-289